Currently Viewing:
Supplements Best Practices for Natalizumab Utilization in the Treatment of Multiple Sclerosis
Recommendations for the Selection, Treatment, and Management of Patients Utilizing Natalizumab Therapy for Multiple Sclerosis
John Foley, MD
The Role of Natalizumab in the Treatment of Multiple Sclerosis
Patricia K. Coyle, MD
Quantifying the Role of Natalizumab in Health and Economic Outcomes in Multiple Sclerosis
David W. Brandes, MS, MD, FAAN; Fadia T. Shaya, PhD, MPH; and Michael W. Pill, PharmD
Currently Reading
Participating Faculty

Participating Faculty

 
Best Practices for Natalizumab Utilization in the Treatment of Multiple Sclerosis
This supplement to The American Journal of Managed Care reviews the clinical and economic burden of multiple sclerosis and summarizes the efficacy and safety of natalizumab. The impact of natalizumab on clinical and economic outcomes is discussed. The role of natalizumab in clinical practice is outlined, with emphasis on selection of appropriate patients for treatment.


Faculty
 
David W. Brandes, MS, MD, FAAN
Hope Neurology
Knoxville, Tennessee
Assistant Clinical Professor, Neurology
University of California, Los Angeles
Los Angeles, California


Patricia K. Coyle, MD
Professor and Acting Chair
Department of Neurology
Stony Brook University Medical Center and Stony Brook MS Comprehensive Care Center
Stony Brook, New York


John Foley, MD
Director
Rocky Mountain Multiple Sclerosis Clinic
Rocky Mountain Neurological Associates
Salt Lake City, Utah


Michael W. Pill, PharmD
President
Gemini Healthcare, LLC
Westbrook, Connecticut


Fadia T. Shaya, PhD, MPH
Associate Professor
University of Maryland School of Pharmacy
Baltimore, Maryland


Faculty Disclosures
These faculty report relationships with the following organizations:


David W. Brandes, MS, MD, FAAN
Consultant/advisory board/honoraria/lectureship:
Bayer
Biogen Idec
EMD Serono
Teva


Patricia K. Coyle, MD
Board membership:
Bayer
Novartis
Consultant/advisory board:
Acorda
Bayer
Biogen Idec
EMD Serono
Pfizer
sanofi-aventis
Teva
Grants:
Novartis
sanofi-aventis
Honoraria/lectureship:
Bayer
Biogen Idec
EMD Serono
Novartis
Pfizer
sanofi-aventis
Teva


John Foley, MD
Advisory board:
Biogen Idec
Honoraria/lectureship:
Biogen Idec
Genentech
Teva


Michael W. Pill, PharmD, and Fadia T. Shaya, PhD, MPH, have nothing to disclose.


This supplement was supported by Biogen Idec Inc.


The contents of this supplement may include information regarding the use of products that may be inconsistent
with or outside the approved labeling for these products in the United States. Physicians should note that the
use of these products outside current approved labeling is considered experimental and are advised to consult
prescribing information for these products.
 
PDF
 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!